Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy

NCT ID: NCT04138472

Last Updated: 2020-02-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-30

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Direct laryngoscopy and intubation are painful stimulus that activates sympathoadrenal discharge which results in intense cardiovascular reflex i.e. tachycardia and hypertension. In this study we will compare effects of intravenous dexmedetomidine, fentanyl and lidocaine for attenuation of these reflexes in patient undergoing laproscopic cholecystectomy. how these agents will effect hemodynamic response during pneumoperitoneum. Tertiary objective will be to observe sedation, perioperative complications and recovery in these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laparoscopic Cholecystectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized control trial
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Patients do not know about the interventions.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine

Group A patients receive intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.

Group Type EXPERIMENTAL

dexmedetomidine

Intervention Type DRUG

intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.

Fentanyl

Group B receives intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.

Group Type EXPERIMENTAL

fentanyl

Intervention Type DRUG

intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.

Lidocaine

Group C patients receives intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.

Group Type EXPERIMENTAL

lidocaine

Intervention Type DRUG

intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dexmedetomidine

intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.

Intervention Type DRUG

fentanyl

intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.

Intervention Type DRUG

lidocaine

intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA-I and ll patients
* Male and female patient of age 20-70 years.
* Undergoing Elective surgery
* Intubation by skilled anesthetist of at least 2 years' experience
* Intubation not more than 45 seconds

Exclusion Criteria

* Patients with uncontrolled DM, HTN, IHD, endocrine or autonomic dysfunction
* Pregnant and lactating females
* Short thick neck with anticipated difficult intubation
* Any sort of obstructive restrictive or reactive airway disease
* Patient allergic to any of the study medications.
* Obese patients, Narcotic addicts
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dow University of Health Sciences

OTHER

Sponsor Role collaborator

Sana Urooj

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sana Urooj

SUrooj

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

DUHS, Civil hospital Karachi (CHK)

Karachi, Sindh, Pakistan

Site Status RECRUITING

DUHS, Civil hospital Karachi (CHK)

Karachi, Sindh, Pakistan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sana Urooj, FCPS

Role: CONTACT

+923333515690

Sana Urooj

Role: CONTACT

03333515690

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

0333351560

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dexmedetomidine in IVRA
NCT05123170 COMPLETED PHASE4
Role of Dexmedetomidine as Synergistic Agent
NCT06662175 NOT_YET_RECRUITING PHASE2/PHASE3